139 related articles for article (PubMed ID: 26912584)
21. Health-related quality of life in patients with long-standing rheumatoid arthritis in the era of biologics: data from the German biologics register RABBIT.
Gerhold K; Richter A; Schneider M; Bergerhausen HJ; Demary W; Liebhaber A; Listing J; Zink A; Strangfeld A
Rheumatology (Oxford); 2015 Oct; 54(10):1858-66. PubMed ID: 26001633
[TBL] [Abstract][Full Text] [Related]
22. Incidence of hip and knee replacement in patients with rheumatoid arthritis following the introduction of biological DMARDs: an interrupted time-series analysis using nationwide Danish healthcare registers.
Cordtz RL; Hawley S; Prieto-Alhambra D; Højgaard P; Zobbe K; Overgaard S; Odgaard A; Kristensen LE; Dreyer L
Ann Rheum Dis; 2018 May; 77(5):684-689. PubMed ID: 29247125
[TBL] [Abstract][Full Text] [Related]
23. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients.
Faurschou M; Sorensen IJ; Mellemkjaer L; Loft AG; Thomsen BS; Tvede N; Baslund B
J Rheumatol; 2008 Jan; 35(1):100-5. PubMed ID: 17937462
[TBL] [Abstract][Full Text] [Related]
24. Less educated and older patients have reduced access to biologic DMARDs even in a country with highly developed social welfare (Norway): results from Norwegian cohort study NOR-DMARD.
Putrik P; Ramiro S; Lie E; Keszei AP; Kvien TK; van der Heijde D; Landewé R; Uhlig T; Boonen A
Rheumatology (Oxford); 2016 Jul; 55(7):1217-24. PubMed ID: 27012686
[TBL] [Abstract][Full Text] [Related]
25. Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden.
Raaschou P; Simard JF; Holmqvist M; Askling J;
BMJ; 2013 Apr; 346():f1939. PubMed ID: 23568792
[TBL] [Abstract][Full Text] [Related]
26. Monitoring patients with rheumatoid arthritis in routine care: experiences from a treat-to-target strategy using the DANBIO registry.
Hetland ML; Jensen DV; Krogh NS
Clin Exp Rheumatol; 2014; 32(5 Suppl 85):S-141-6. PubMed ID: 25365104
[TBL] [Abstract][Full Text] [Related]
27. Risk of malignancy in rheumatoid arthritis patients initiating biologics: an historical propensity score matched cohort study within the French nationwide healthcare database.
Seror R; Lafourcade A; De Rycke Y; Pinto S; Castaneda J; Fautrel B; Mariette X; Tubach F
RMD Open; 2022 Jun; 8(2):. PubMed ID: 35738803
[TBL] [Abstract][Full Text] [Related]
28. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis.
Setoguchi S; Solomon DH; Weinblatt ME; Katz JN; Avorn J; Glynn RJ; Cook EF; Carney G; Schneeweiss S
Arthritis Rheum; 2006 Sep; 54(9):2757-64. PubMed ID: 16947774
[TBL] [Abstract][Full Text] [Related]
29. Validity of data collected in BIOREG, the Austrian register for biological treatment in rheumatology: current practice of bDMARD therapy in rheumatoid arthritis in Austria.
Rintelen B; Zwerina J; Herold M; Singer F; Hitzelhammer J; Halder W; Eichbauer-Sturm G; Puchner R; Stetter M; Leeb BF;
BMC Musculoskelet Disord; 2016 Aug; 17(1):358. PubMed ID: 27550175
[TBL] [Abstract][Full Text] [Related]
30. Drug survival of second biological DMARD therapy in patients with rheumatoid arthritis: a retrospective non-interventional cohort analysis.
Wilke T; Mueller S; Lee SC; Majer I; Heisen M
BMC Musculoskelet Disord; 2017 Aug; 18(1):332. PubMed ID: 28764705
[TBL] [Abstract][Full Text] [Related]
31. Comparison of active tuberculosis occurrence associated with Janus kinase inhibitors and biological DMARDs in rheumatoid arthritis.
Song YK; Lee J; Jo J; Kwon JW
RMD Open; 2024 Apr; 10(2):. PubMed ID: 38609319
[TBL] [Abstract][Full Text] [Related]
32. Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: analysis of the Australian Rheumatology Association Database (ARAD) prospective cohort study.
Buchbinder R; Van Doornum S; Staples M; Lassere M; March L
BMC Musculoskelet Disord; 2015 Oct; 16():309. PubMed ID: 26481039
[TBL] [Abstract][Full Text] [Related]
33. Risk of serious infections in arthritis patients treated with biological drugs: a matched cohort study and development of prediction model.
Krabbe S; Grøn KL; Glintborg B; Nørgaard M; Mehnert F; Jarbøl DE; Østergaard M; Hetland ML
Rheumatology (Oxford); 2021 Aug; 60(8):3834-3844. PubMed ID: 33493342
[TBL] [Abstract][Full Text] [Related]
34. Disease-modifying antirheumatic drugs and risk of thyroxine-treated autoimmune thyroid disease in patients with rheumatoid arthritis.
Waldenlind K; Delcoigne B; Saevarsdottir S; Askling J
J Intern Med; 2024 Mar; 295(3):313-321. PubMed ID: 37990795
[TBL] [Abstract][Full Text] [Related]
35. Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population.
Mercer LK; Davies R; Galloway JB; Low A; Lunt M; Dixon WG; Watson KD; Symmons DP; Hyrich KL;
Rheumatology (Oxford); 2013 Jan; 52(1):91-8. PubMed ID: 23238979
[TBL] [Abstract][Full Text] [Related]
36. Ten-year retrospective review of the incidence of serious infections in patients on biologic disease modifying agents for rheumatoid arthritis in three tertiary hospitals in Western Australia.
Sharma C; Keen H
Intern Med J; 2019 Apr; 49(4):519-525. PubMed ID: 30230146
[TBL] [Abstract][Full Text] [Related]
37. The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study.
An Y; Liu T; He D; Wu L; Li J; Liu Y; Bi L; Zhou B; Lin C; He L; Liu X; Li X; Yang N; Zhang Z; Song H; Wei W; Liu J; Bi Y; Li Z
Clin Rheumatol; 2017 Jan; 36(1):35-43. PubMed ID: 27709444
[TBL] [Abstract][Full Text] [Related]
38. Rates, factors, reasons, and economic impact associated with switching in rheumatoid arthritis patients newly initiated on biologic disease modifying anti-rheumatic drugs in an integrated healthcare system.
Rashid N; Lin AT; Aranda G; Lin KJ; Guerrero VN; Nadkarni A; Patel C
J Med Econ; 2016 Jun; 19(6):568-75. PubMed ID: 26766553
[TBL] [Abstract][Full Text] [Related]
39. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
[TBL] [Abstract][Full Text] [Related]
40. Rheumatoid arthritis and the risk of malignancy.
Cibere J; Sibley J; Haga M
Arthritis Rheum; 1997 Sep; 40(9):1580-6. PubMed ID: 9324011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]